NDA 17-037/S-158
Page 20
Administration of protamine sulfate can cause severe hypotensive and anaphylactoid reactions.
Because fatal reactions often resembling anaphylaxis have been reported, the drug should be given
only when resuscitation techniques and treatment of anaphylactoid shock are readily available.
For additional information consult the labeling of Protamine Sulfate Injection, USP products.
DOSAGE AND ADMINISTRATION
Parenteral drug products should be inspected visually for particulate matter and discoloration
prior to administration, whenever solution and container permit. Slight discoloration does not
alter potency.
Heparin Lock Flush Solution is not recommended for use in neonates (see
WARNINGS,
Use In
Neonates).
Maintenance Of Patency Of Intravenous Devices
To prevent clot formation in a heparin lock set or central venous catheter following its proper insertion,
Heparin Lock Flush Solution, USP is injected via the injection hub in a quantity sufficient to fill the
entire device. This solution should be replaced each time the device is used. Aspirate before
administering any solution via the device in order to confirm patency and location of needle or catheter
tip. If the drug to be administered is incompatible with heparin, the entire device should be flushed
with normal saline before and after the medication is administered; following the second saline flush,
Heparin Lock Flush Solution, USP may be reinstilled into the device. The device manufacturer's
instructions should be consulted for specifics concerning its use. Usually this dilute heparin solution
will maintain anticoagulation within the device for up to 4 hours.
NOTE: Since repeated injections of small doses of heparin can alter tests for activated partial
thromboplastin time (APTT), a baseline value for APTT should be obtained prior to insertion of an
intravenous device.
Dostları ilə paylaş: